Profile data is unavailable for this security.
About the company
MAXIGEN BIOTECH INC. is a Taiwan-based company principally engaged in the manufacture and sales of biological products, the wholesale of all kinds of medical equipment, medicines, foods, masks, skin care products, as well as the manufacture and sales of chemical materials. The Company operates through two main segments. The Consumer Products segment is mainly engaged in the wholesales of cleansing products, facial care products, medical beauty products and others. The Biomedical Products is mainly involved in the manufacture and sales of Formagraft collagen and ceramic composite material products, Foramic ceramic bone feed materials, Artiaid hyaluronic acid joint injection products, ViscAid ophthalmology viscoelastic agents, as well as SurgiAid wound collagen materials and others.
- Revenue in TWD (TTM)792.49m
- Net income in TWD234.07m
- Incorporated1998
- Employees96.00
- LocationMaxigen Biotech IncNo.88, Keji 1st Road, Guishan DistrictTAOYUAN 333TaiwanTWN
- Phone+886 33287222
- Fax+886 33287333
- Websitehttps://mbi-bio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mao Bao INC | 653.97m | 15.40m | 1.17bn | 198.00 | 76.28 | 2.41 | 40.36 | 1.79 | 0.3625 | 0.3625 | 15.40 | 11.48 | 1.02 | 3.71 | 7.50 | -- | 2.40 | 2.14 | 2.98 | 2.73 | 40.73 | 40.56 | 2.36 | 2.34 | 2.36 | 3.08 | 0.0216 | 82.17 | 7.02 | -0.0974 | 308.34 | -12.68 | 25.16 | -- |
| Jourdeness Group Ltd | 2.24bn | -142.24m | 1.79bn | -- | -- | 1.11 | 3.56 | 0.7959 | -2.40 | -2.40 | 37.81 | 26.08 | 0.297 | 2.78 | 12.79 | -- | -1.88 | 0.7067 | -3.49 | 1.29 | 62.44 | 69.50 | -6.34 | 2.00 | 0.3824 | -1.91 | 0.6465 | 201.49 | -23.36 | -6.85 | -113,057.40 | -- | -7.93 | -34.02 |
| Luo Lih Fen Holding Co Ltd | 1.09bn | 113.03m | 2.06bn | -- | 18.22 | 1.26 | 12.32 | 1.89 | 2.38 | 2.38 | 23.04 | 34.44 | 0.489 | 4.64 | 143.52 | -- | 4.75 | 3.77 | 6.16 | 4.57 | 64.24 | 60.94 | 9.71 | 8.43 | 1.71 | -- | 0.0317 | 94.02 | 16.01 | -4.87 | -8.50 | -30.50 | -18.90 | -22.16 |
| Kuangli Bio Tech Holdings Co Ltd | 387.37m | -193.36m | 2.59bn | -- | -- | 4.24 | -- | 6.69 | -2.29 | -2.29 | 4.47 | 6.27 | 0.3654 | 6.23 | 6.01 | -- | -18.24 | -7.41 | -24.93 | -10.93 | 18.27 | 20.59 | -49.92 | -23.32 | 1.39 | -10.31 | 0.4136 | -- | 29.97 | -2.16 | -65.89 | -- | 41.96 | -- |
| Maywufa Co Ltd | 1.55bn | 174.62m | 2.92bn | 282.00 | 16.74 | 1.40 | 12.74 | 1.89 | 1.31 | 1.31 | 11.60 | 15.68 | 0.4994 | 1.98 | 5.89 | -- | 5.64 | 6.22 | 6.51 | 7.24 | 63.65 | 65.27 | 11.30 | 13.15 | 2.14 | 41.42 | 0.2356 | 88.98 | 14.23 | 6.18 | 2.44 | 11.48 | 118.16 | 14.87 |
| KNH Enterprise Co Ltd | 2.74bn | -369.74m | 3.28bn | 1.04k | -- | 1.45 | -- | 1.20 | -1.89 | -1.89 | 14.04 | 11.58 | 0.4194 | 3.70 | 3.33 | -- | -5.66 | 2.90 | -7.37 | 3.83 | 6.17 | 16.80 | -13.48 | 5.49 | 1.74 | -9.79 | 0.5787 | 76.70 | -0.034 | -6.26 | -155.94 | -- | 2.45 | 0.00 |
| Farcent Enterprise Co Ltd | 2.44bn | 280.16m | 3.36bn | 350.00 | 12.01 | 1.72 | 9.54 | 1.38 | 4.43 | 4.43 | 38.61 | 30.84 | 0.9567 | 4.84 | 6.22 | -- | 12.23 | 11.43 | 15.95 | 15.79 | 50.33 | 46.00 | 12.78 | 10.55 | 3.00 | -- | 0.0312 | 73.68 | -3.48 | -5.73 | 8.25 | -5.94 | -23.66 | -4.42 |
| Maxigen Biotech Inc | 792.49m | 234.07m | 3.97bn | 96.00 | 17.02 | 2.70 | 15.07 | 5.01 | 2.60 | 2.60 | 8.81 | 16.43 | 0.4891 | 3.11 | 7.31 | -- | 14.45 | 9.87 | 16.62 | 11.15 | 69.33 | 61.07 | 29.54 | 22.47 | 3.84 | -- | 0.00 | 40.53 | 9.41 | 8.52 | 14.68 | 25.90 | 6.00 | 4.21 |
| Holder | Shares | % Held |
|---|---|---|
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 465.85k | 0.52% |
| DFA Australia Ltd.as of 31 Dec 2025 | 11.45k | 0.01% |
